ART0380

PreclinicalSmall molecule

AArtios Pharma Ltd

ART0380 is one of 44 small molecule programs targeting Advanced Cancer. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Advanced CancerRecruiting

Advanced CancerPreclinical

Recruiting

Competition

Competitive Landscape

67 competitors in Advanced Cancer

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 2

12 2

Taxol

Teva

Phase 2

12 3

Gemzar

Johnson & Johnson

Phase 2

8 4

Camptosar

Pfizer

Phase 2

8 5

Opdivo

Bristol-Myers Squibb

Phase 2

6 6

Verzenio

Eli Lilly

Phase 2

4 7

Elunate

Takeda

Phase 2

1 8

Taxotere

AAvyxa

Phase 2

9 9

Torisel

PPrism Pharmaceuticals

Phase 2

5 10

Paraplatin

AAvyxa

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

PreclinicalRecruiting

Advanced Cancer

NCT04657068

Clinical

Trials by Indication[1]

Solid Tumors1 trial

Study of ART0380 in Patients With Biologically Selected Solid Tumors

Terminated·AArtios Pharma Ltd·Phase 2·NCT05798611·36 enrolled

Advanced Cancer1 trial

A Phase I/IIa, Open-label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients With Advanced or Metastatic Solid Tumors

Recruiting·AArtios Pharma Ltd·Preclinical·NCT04657068·542 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for ART0380. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ART0380 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ART0380. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Artios Pharma Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: AArtios Pharma Ltd

ART0380

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

Solid Tumors1 trial

Advanced Cancer1 trial

References

Drug Info

Quick Facts

Related News